Kari Grønås
Directeur/Bestuurslid bij SPAGO NANOMEDICAL AB
Vermogen: 4 185 $ op 30-04-2024
Profiel
Kari Grønås currently works at Spago Nanomedical AB, as Independent Director from 2018, Ultimovacs ASA, as Director from 2019, K & K AS, as Managing Director & Director from 2012, Norwegian Cancer Society, as Director, and Arxx Therapeutics AS, as Director.
Ms. Grønås also formerly worked at Norwegian Pharmaceutical Society, as Chairman, Oncopeptides AB, as Director, Lytix Biopharma AS, as Director, BerGenBio ASA, as Independent Non-Executive Director from 2016 to 2019, SoftOx Solutions AS, as Non-Executive Director, and Algeta ASA, as Senior Vice President-Operations.
Ms. Grønås received her graduate degree from the University of Oslo.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ULTIMOVACS AS
0.02% | 31-12-2022 | 6 640 ( 0.02% ) | 4 185 $ | 30-04-2024 |
Actieve functies van Kari Grønås
| Bedrijven | Functie | Begin |
|---|---|---|
| SPAGO NANOMEDICAL AB | Directeur/Bestuurslid | 01-01-2018 |
| ULTIMOVACS ASA | Directeur/Bestuurslid | 01-01-2019 |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Algemeen Directeur | 21-05-2012 |
| Norwegian Cancer Society | Directeur/Bestuurslid | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Kari Grønås
| Bedrijven | Functie | Einde |
|---|---|---|
| BERGENBIO ASA | Directeur/Bestuurslid | 13-03-2019 |
| ONCOPEPTIDES AB | Directeur/Bestuurslid | - |
| SOFTOX SOLUTIONS | Directeur/Bestuurslid | - |
| Norwegian Pharmaceutical Society | Voorzitter | - |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░ ░░░░░░░░░ | - |
Opleiding van Kari Grønås
| University of Oslo | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| BERGENBIO ASA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| Bedrijven in privébezit | 5 |
|---|---|
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
